Fennec Pharmaceuticals Q3 EPS $(0.02), Inline, Sales $12.462M Beat $11.257M Estimate
Benzinga Newsdesk 11 months ago
EarningsEarnings BeatsNews
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 90.48 percent increase over losses of $(0.21) per share from the same period last
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 90.48 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $12.462 million which beat the analyst consensus estimate of $11.257 million by 10.71 percent. This is a 78.69 percent increase over sales of $6.974 million the same period last year.